Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to determine the percentage of people who can attain remission and the length of time such responses to therapy are sustained, as well as the side effects that might result from rituximab and thalidomide in people with lymphoplasmacytic lymphoma.


Clinical Trial Description

- Patients will receive thalidomide(200mg) orally once daily for two weeks. If after two weeks of thalidomide, the patient is doing well the dose of thalidomide will increase (400mg) and they will remain on it for up to 50 additional weeks. The length of time a patient is on thalidomide will depend upon how they are responding to therapy.

- During the second week of the study patients will also begin receiving rituximab intravenously once weekly for 4 weeks, which may then be repeated 8 weeks later depending upon the response.

- A determination of how the patient is responding will be made based on testing conducted at 12 weeks. This testing includes blood tests and possibly a bone marrow biopsy. If it is determined that the disease is not progressing, patients will begin a second phase of treatment which includes 4 additional weekly infusions of rituximab and the continuation of oral thalidomide.

- If it is determined at the 12-week evaluation, or at any time thereafter, that the disease has progressed (by studying serum immunoglobulin M (IgM) levels, bone marrow involvement, tumor cells, and/or development of new signs and symptoms) then the patient will be removed from the study.

- Periodic examinations and tests will be done to determine how the patient is doing, what response and side effects (if any) the patient may be having from the study drugs. If patient is responding to therapy then they will remain on this study and followed for a period of two years.

- Bone marrow biopsies and aspirations will be obtained at 3-6 month intervals extending for 2 years following the last treatment. ;


Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00142116
Study type Interventional
Source Dana-Farber Cancer Institute
Contact
Status Completed
Phase Phase 2
Start date May 2003
Completion date February 2008

See also
  Status Clinical Trial Phase
Recruiting NCT04883437 - Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas Phase 2
Recruiting NCT04545762 - Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma Phase 1
Active, not recruiting NCT03133221 - 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation Phase 2
Completed NCT03019666 - Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL Phase 1
Recruiting NCT03335098 - Study of VTD in Waldenstrom's Macroglobulinemia Phase 2
Active, not recruiting NCT00719888 - Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease Phase 2
Recruiting NCT00923507 - Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)
Completed NCT01314014 - Imexon for Relapsed Follicular and Aggressive Lymphomas Phase 2
Recruiting NCT04799275 - Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma Phase 2/Phase 3
Active, not recruiting NCT02339922 - Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma Phase 2
Terminated NCT03601819 - Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders Phase 1
Active, not recruiting NCT02722668 - UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep Phase 2
Completed NCT02661035 - Allo HSCT Using RIC for Hematological Diseases Phase 2
Recruiting NCT03314974 - Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders Phase 2
Recruiting NCT06340737 - AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas Phase 1
Completed NCT00142181 - Phase II Study of Campath-1H Antibody to Treat Waldenstrom's Macroglobulinemia Phase 2
Completed NCT01282424 - Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas Phase 2
Completed NCT04858568 - Immune Responses to COVID-19 Vaccination in Lymphoma Patients
Completed NCT00644189 - Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma Phase 1/Phase 2
Completed NCT00566332 - Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia Phase 3